Each person with breast cancer is unique. Past therapies were developed by testing treatments within broad groups of patients, such as estrogen positive or HER-2 positive for example. We know that even within such subgroups, there is diversity at the molecular level. Not all breast cancers of the same "type" are the same. This presentation will provide an update on how precision molecular oncology is informing a more personalized approach to the understanding and therapy of breast cancer.
Presented by: Gary Grad, MD, Medical Oncologist, Isreal Cancer Research Fund